TNF/TNFR family members in costimulation of T cell responses

Annual Review of Immunology

Volumn 23, Issue , 2005, Pages 23-68

  Watts, Tania H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Survival signaling; T cell memory; T effector cell

Indexed keywords

ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD70 ANTIGEN; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR FAMILY RELATED GENE PROTEIN; HERPES VIRUS ENTRY MEDIATOR PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER THERAPY; CELL MIGRATION; CELL STIMULATION; CELL SURVIVAL; CELL TYPE; CELLULAR IMMUNITY; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNITY; IN VIVO STUDY; INFECTION; LONGEVITY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD27; ANTIGENS, CD30; ANTIGENS, CD70; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17644389199     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.23.021704.115839     Document Type: Review

References (311)

1. Lenschow DJ, Walunas TL, Bluestone JA. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233-58
2. Sharpe AH, Freeman GJ. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116-26
3. Wong P, Pamer EG. 2003. CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol. 21:29-70
4. + T cell clonal expansion. J. Immunol. 168:1682-89
5. Sprent J, Surh CD. 2002. T cell memory. Annu. Rev. Immunol. 20:551-79
6. Kollias G, Kontoyiannis D. 2002. Role of TNF/TNFR in autoimmunity: Specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 13:315-21
7. Pfeffer K. 2003. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 14:185-91
8. Gommerman JL, Browning JL. 2003. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat. Rev. Immunol. 3:642-55
9. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, et al. 2000. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191:495-502
10. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189:1025-31
11. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. 2004. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22:307-28
12. Croft M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3:609-20
13. - lymphocytes by 4-1BB ligand. J. Immunol. 158:551-59
14. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. 1997. Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159:3838-48
15. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, et al. 2000. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191:365-74
16. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, et al. 2002. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14:275-86
17. Diehl L, van Mierlo GJ, den Boer AT, van der Voort E, Fransen M, et al. 2002. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J. Immunol. 168:3755-62
18. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, et al. 2003. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170:33-40
19. Kim EY, Teh HS. 2001. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol. 167:6812-20
20. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501
21. Dempsey PW, Doyle SE, He JQ, Cheng G. 2003. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14:193-209
22. Aggarwal BB. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3:745-56
23. Chung JY, Park YC, Ye H, Wu H. 2002. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 115:679-88
24. Arch RH, Gedrich RW, Thompson CB. 1998. Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death. Genes Dev. 12:2821-30
25. Ye H, Wu H. 2000. Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry. Proc. Natl. Acad. Sci. USA 97:8961-66
26. Karin M, Lin A. 2002. NF-κB at the crossroads of life and death. Nat. Immunol. 3:221-27
27. Yamamoto H, Kishimoto T, Minamoto S. 1998. NF-κB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27. J. Immunol. 161:4753-59
28. Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, et al. 1998. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAP5, and NF-κβ-inducing kinase. J. Biol. Chem. 273:13353-58
29. Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T. 1998. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2-and TRAF5-mediatedNF-κB activation. J. Biol. Chem. 273:5808-14
30. Arch RH, Thompson CB. 1998. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol. Cell. Biol. 18:558-65
31. Jang IK, Lee ZH, Kim YJ, Kim SH, Kwon BS. 1998. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-κB. Biochem. Biophys. Res. Comm. 242:613-20
32. L and Bfl-1. J. Immunol. 169:4882-88
33. Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, et al. 1996. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc. Natl. Acad. Sci. USA 93:14053-58
34. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. 1997. Induction of nuclear factor κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol. Cell. Biol. 17:1535-42
35. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, et al. 1997. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-κB activation. J. Biol. Chem. 272:2042-45
36. Harlin H, Podack E, Boothby M, Alegre ML. 2002. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J. Immunol. 169:2451-59
37. Harrop JA, McDonnell PC, Brigham-Burke M, Lyn SD, Minton J, et al. 1998. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J. Biol. Chem. 273:27548-56
38. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. 1997. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J. Biol. Chem. 272:14029-32
39. Kwon B, Yu KY, Ni J, Yu GL, Jang IK, et al. 1999. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J. Biol. Chem. 274:6056-61
40. Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, et al. 1999. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr. Biol. 9:215-18
41. Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, et al. 2004. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J. Immunol. 172:5823-27
42. + T cells. J. Immunol. 172:7306-14
43. Gravestein LA, Amsen D, Boes M, Calvo CR, Kruisbeek AM, Borst J. 1998. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur. J. Immunol. 28:2208-16
44. Cannons JL, Hoeflich KP, Woodgett JR, Watts TH. 1999. Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. J. Immunol. 163:2990-98
45. Cannons JL, Choi Y, Watts TH. 2000. Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J. Immunol. 165:6193-204
46. Arron JR, Pewzner-Jung Y, Walsh MC, Kobayashi T, Choi Y. 2002. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J. Exp. Med. 196:923-34
47. Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, et al. 1997. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715-25
48. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. 1997. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity 7:703-13
49. Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, et al. 2001. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-κB activation and protection from cell death. J. Biol. Chem. 276:36530-34
50. Saoulli K, Lee SY, Cannons JL, Yeh WC, Santana A, et al. 1998. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187:1849-62
51. Prell RA, Evans DE, Thalhofer C, Shi T, Funatake C, Weinberg AD. 2003. OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J. Immunol. 171:5997-6005
52. So T, Salek-Ardakani S, Nakano H, Ware CF, Croft M. 2004. TNF receptor-associated factor 5 limits the induction of Th2 immune responses. J. Immunol. 172:4292-97
53. Nakano H, Sakon S, Koseki H, Takemori T, Tada K, et al. 1999. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc. Natl. Acad. Sci. USA 96:9803-8
54. L and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15:445-55
55. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M. 2004. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat. Immunol. 5:150-56
56. L levels in vivo. J. Exp. Med. 191:1721-34
57. Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, et al. 1997. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc. Natl. Acad. Sci. USA 94:6346-51
58. Spinicelli S, Nocentini G, Ronchetti S, Krausz LT, Bianchini R, Riccardi C. 2002. GITR interacts with the pro-apoptotic protein Siva and induces apoptosis. Cell Death Differ. 9:1382-84
59. Py B, Slomianny C, Auberger P, Petit PX, Benichou S. 2004. Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway. J. Immunol. 172:4008-17
60. Kim YJ, Pollok KE, Zhou Z, Shaw A, Bohlen JB, et al. 1993. Novel T cell antigen 4-1BB associates with the protein tyrosine kinase p561ck1. J. Immunol. 151:1255-62
61. Lens SM, Tesselaar K, van Oers MH, van Lier RA. 1998. Control of lymphocyte function through CD27-CD70 interactions. Semin. Immunol. 10:491-99
62. Borst J, Sluyser C, De Vries E, Klein H, Melief CJ, Van Lier RA. 1989. Alternative molecular form of human T cell-specific antigen CD27 expressed upon T cell activation. Eur. J. Immunol. 19:357-64
63. de Jong R, Loenen WA, Brouwer M, van Emmerik L, de Vries EF, et al. 1991. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J. Immunol. 146:2488-94
64. - cells are induced by antigen and evolve through extensive rounds of division. Int. Immunol. 11:1027-33
65. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:379-85
66. + T lymphocytes depend on infection with CMV. J. Immunol. 170:4342-48
67. + T cells is associated with progression to viral disease in HIV-infection. AIDS 16:2001-11
68. + T-cell maturation: CD27 might provide a clue. Trends Immunol. 23:586-91
69. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225-34
70. Gravestein LA, van Ewijk W, Ossendorp F, Borst J. 1996. CD27 cooperates with the pre-T cell receptor in the regulation of murine T cell development. J. Exp. Med. 184:675-85
71. Hendriks J, Gravestein LA, Tesselaar K, van Lier RAW, Schumacher TNM, Borst J. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1:433-40
72. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. 1994. The cloning of CD70 and its identification as the ligand for CD27. J. Immunol. 152:1756-61
73. Tesselaar K, Gravestein LA, van Schijndel GM, Borst J, van Lier RA. 1997. Characterization of murine CD70, the ligand of the TNF receptor family member CD27. J. Immunol. 159:4959-65
74. Oshima H, Nakano H, Nohara C, Kobata T, Nakajima A, et al. 1998. Characterization of murine CD70 by molecular cloning and mAb. Int. Immunol. 10:517-26
75. Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, et al. 2000. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental Leishmaniasis. J. Exp. Med. 191:375-80
76. Camerini D, Walz G, Loenen WA, Borst J, Seed B. 1991. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J. Immunol. 147:3165-69
77. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, et al. 1993. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73:447-56
78. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. 1995. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J. Immunol. 154:2612-23
79. Gravestein LA, Nieland JD, Kruisbeek AM, Borst J. 1995. Novel mAbs reveal potent co-stimulatory activity of murine CD27. Int. Immunol 7:551-57
80. Stuhler G, Zobywalski A, Grunebach F, Brossart P, Reichardt VL, et al. 1999. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc. Natl Acad. Sci. USA 96:1532-35
81. Hendriks J, Xiao Y, Borst J. 2003. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J. Exp. Med. 198:1369-80
82. Nagumo H, Agematsu K, Shinozaki K, Hokibara S, Ito S, et al. 1998. CD27/CD70 interaction augments IgE secretion by promoting the differentiation of memory B cells into plasma cells. J. Immunol. 161:6496-502
83. Raman VS, Akondy RS, Rath S, Bal V, George A. 2003. Ligation of CD27 on B cells in vivo during primary immunization enhances commitment to memory B cell responses. J. Immunol. 171:5876-81
84. Xiao Y, Hendriks J, Langerak P, Jacobs H, Borst J. 2004. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J. Immunol. 172:7432-41
85. Arens R, Tesselaar K, Baars PA, van Schijndel GM, Hendriks J, et al. 2001. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNγ-mediated B cell depletion. Immunity 15:801-12
86. + T cell formation. J. Exp. Med. 199:1595-605
87. + cytotoxic T cell responses in vivo. J. Immunol. 172:6039-46
88. Nakajima A, Oshima H, Nohara C, Morimoto S, Yoshino S, et al. 2000. Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 109:188-96
89. Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, et al. 1998. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 5:163-75
90. Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM. 1998. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J. Immunother. 21:225-36
91. Lorenz MG, Kantor JA, Schlom J, Hodge JW. 1999. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum. Gene Ther. 10:1095-103
92. Wu T, Hering B, Kirchof N, Sutherland D, Yagita H, Guo Z. 2001. The effect of OX40/OX40L and CD27/CD70 pathways on allogeneic islet graft rejection. Transplant Proc. 33:217-18
93. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, et al. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3:83-90
94. Paterson DJ, Jefferies WA, Green JR, Brandon MR, Corthesy P, et al. 1987. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol. Immunol. 24:1281-90
95. Weinberg AD, Vella AT, Croft M. 1998. OX-40: life beyond the effector T cell stage. Semin. Immunol. 10:471-80
96. Sugamura K, Ishii N, Weinberg AD. 2004. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4:420-31
97. Shimojima M, Miyazawa T, Ikeda Y, McMonagle EL, Haining H, et al. 2004. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303:1192-95
98. Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, et al. 2002. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 32:3617-27
99. Baum PR, Gayle RB III, Ramsdell F, Srinivasan S, Sorensen RA, et al. 1994. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 13:3992-4001
100. Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, et al. 2001. 4-1BBL induces cell division, sustains survival and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167:1313-24
101. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. 2004. Costimulation of CD8 T cell responses by OX40. J. Immunol. 172:4821-25
102. +) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 98:3162-64
103. + intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-γ, and IL-10 regulation. J. Immunol. 167:6717-23
104. Gramaglia I, Weinberg AD, Lemon M, Croft M. 1998. OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510-17
105. Walker LS, Gulbranson-Judge A, Flynn S, Brocker T, Raykundalia C, et al. 1999. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J. Exp. Med. 190:1115-22
106. Roos A, Schilder-Tol EJ, Weening JJ, Aten J. 1998. Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment. J. Leukoc. Biol. 64:503-10
107. - accessory cells co-stimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells. Immunity 18:643-54
108. Rogers PR, Croft M. 2000. CD28, Ox40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J. Immunol. 164:2955-63
109. Stuber E, Strober W. 1996. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J. Exp. Med. 183:979-89
110. Tanaka Y, Inoi T, Tozawa H, Yamamoto N, Hinuma Y. 1985. A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). Int. J. Cancer 36:549-55
111. Miura S, Ohtani K, Numata N, Niki M, Ohbo K, et al. 1991. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I trans activator p40tax. Mol. Cell. Biol. 11:1313-25
112. + T cells with homology to tumor necrosis factor. J. Exp. Med. 180:757-62
113. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W. 1995. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2:507-21
114. Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, et al. 1999. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol. 162:7058-66
115. + T cells into high IL-4-producing effectors. Blood 92:3338-45
116. Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, et al. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 11:689-98
117. Fillatreau S, Gray D. 2003. T cell accumulation in B cell follicles is regulated by dendritic cells and is independent of B cell activation. J. Exp. Med. 197:195-206
118. Ito T, Amakawa R, Inaba M, Hori T, Ota M, et al. 2004. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J. Immunol. 172:4253-59
119. Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, et al. 1996. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 183:2185-95
120. Kunitomi A, Hori T, Imura A, Uchiyama T. 2000. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system. J. Leukoc. Biol. 68:111-18
121. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. 1999. Blocking OX40/OX40 ligand interaction in vitro and in vivo leads to decreased T-cell function and amelioration of EAE. J. Immunol. 162:1818-26
122. Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, et al. 2000. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30:2815-23
123. Malmstrom V, Shipton D, Singh B, Al-Shamkhani A, Puklavec MJ, et al. 2001. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J. Immunol. 166:6972-81
124. Sato T, Ishii N, Murata K, Kikuchi K, Nakagawa S, et al. 2002. Consequences of OX40-OX40 ligand interactions in Langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice. Eur. J. Immunol. 32:3326-35
125. Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ. 2000. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J. Am. Soc. Nephrol. 11:1426-38
126. Tateyama M, Fujihara K, Ishii N, Sugamura K, Onodera Y, Itoyama Y. 2002. Expression of OX40 in muscles of polymyositis and granulomatous myopathy. J. Neurol. Sci. 194:29-34
127. Stuber E, Buschenfeld A, Luttges J, Von Freier A, Arendt T, Folsch UR. 2000. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur. J. Clin. Invest. 30:594-99
128. Giacomelli R, Passacantando A, Perricone R, Parzanese I, Rascente M, et al. 2001. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. Clin. Exp. Rheumatol. 19:317-20
129. Carboni S, Aboul-Enein F, Waltzinger C, Killeen N, Lassmann H, Pena-Rossi C. 2003. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J. Neuroimmunol. 145:1-11
130. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. 2000. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165:3043-50
131. + T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. J. Immunol. 167:6804-11
132. De Smedt T, Smith J, Baum P, Fanslow W, Butz E, Maliszewski C. 2002. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168:661-70
133. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane R 1998. CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188:297-304
134. + T cells into high IL-4-producing effectors. Int. Arch. Allergy Immunol. 118:384-86
135. Jember AG, Zuberi R, Liu FT, Croft M. 2001. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J. Exp. Med. 193:387-92
136. Linton PJ, Bautista B, Biederman E, Bradley ES, Harbertson J, et al. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197:875-83
137. Hoshino A, Tanaka Y, Akiba H, Asakura Y, Mita Y, et al. 2003. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur. J. Immunol. 33:861-69
138. Ishii N, Ndhlovu LC, Murata K, Sato T, Kamanaka M, Sugamura K. 2003. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses. Eur. J. Immunol. 33:2372-81
139. Salek-Ardakani S, Song J, Halteman BS, Jember AG, Akiba H, et al. 2003. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198:315-24
140. + T cells. Int. Immunol. 10:453-61
141. Humphreys IR, Edwards L, Walzl G, Rae AJ, Dougan G, et al. 2003. OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J. Immunol. 170:6125-32
142. Arestides RS, He H, Westlake RM, Chen AI, Sharpe AH, et al. 2002. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur. J. Immunol. 32:2874-80
143. Maxwell JR, Weinberg A, Prell RA, Vella AT. 2000. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164:107-12
144. Kopf M, Ruedl C, Schmitz N, Gallimore A, Lefrang K, et al. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11:699-708
145. Pippig SD, Pena-Rossi C, Long J, Godfrey WR, Fowell DJ, et al. 1999. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J. Immunol. 163:6520-29
146. Blazar BR, Sharpe AH, Chen AI, Panoskaltsis-Mortari A, Lees C, et al. 2003. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 101:3741-48
147. Brocker T, Gulbranson-Judge A, Flynn S, Riedinger M, Raykundalia C, Lane P. 1999. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29:1610-16
148. Murata K, Nose M, Ndhlovu LC, Sato T, Sugamura K, Ishii N. 2002. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J. Immunol. 169:4628-36
149. Kato H, Kojima H, Ishii N, Hase H, Imai Y, et al. 2004. Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations. J. Clin. Immunol. 24:237-48
150. a. Dawicki W, Bertram EM, Sharpe AH, Watts TH. 2004. 4-1BB and OX40 act independently to facilitate robust CDS and CD4 recall responses. J. Immunol. 173:5944-51
151. Obermeier F, Schwarz H, Dunger N, Strauch UG, Grunwald N, et al. 2003. OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur. J. Immunol. 33:3265-74
152. Kotani A, Hori T, Matsumura Y, Uchiyama T. 2002. Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5. Immunol. Lett. 84:1-7
153. Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. 2003. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J. Exp. Med. 198:1237-42
154. Zubairi S, Sanos SL, Hill S, Kaye PM. 2004. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol. 34:1433-40
155. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, et al. 1996. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med. 2:183-89
156. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K. 2001. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J. Immunol. 167:2991-99
157. Weinberg AD, Lemon M, Jones AJ, Vainiene M, Celnik B, et al. 1996. OX-40 antibody enhances for autoantigen specific Vβ8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J. Neurosci. Res. 43:42-49
158. Higgins LM, McDonald SA, Whittle N, Crockett N, Shields JG, MacDonald TT. 1999. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J. Immunol. 162:486-93
159. Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, et al. 2003. Therapeutic effect of anti-OX40L and anti-TNF-α MAbs in a murine model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284:0595-603
160. Martin-Orozco N, Chen Z, Poirot L, Hyatt E, Chen A, et al. 2003. Paradoxical dampening of anti-islet self-reactivity but promotion of diabetes by OX40 ligand. J. Immunol. 171:6954-60
161. Burgess JK, Carlin S, Pack RA, Arndt GM, Au WW, et al. 2004. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J. Allergy Clin. Immunol. 113:683-89
162. Bansal-Pakala P, Jember AG, Croft M. 2001. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7:907-12
163. Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, Parker DC. 2004. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J. Immunol. 172:6735-43
164. Stuber E, von Freier A, Marinescu D, Folsch UR. 1998. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology 115:1205-15
165. Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. 2000. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 95:2434-39
166. Demirci G, Amanullah F, Kewalaramani R, Yagita H, Strom TB, et al. 2004. Critical role of OX40 in CD28 and CD154-independent rejection. J. Immunol. 172:1691-98
167. Gri G, Gallo E, Di Carlo E, Musiani P, Colombo MP. 2003. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J. Immunol. 170:99-106
168. Yanagita S, Hori T, Matsubara Y, Ishikawa T, Uchiyama T. 2004. Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity. Br. J. Haematol. 124:454-62
169. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, et al. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164:2160-69
170. Gerloni M, Xiong S, Mukerjee S, Schoenberger SP, Croft M, Zanetti M. 2000. Functional cooperation between T helper cell determinants. Proc. Natl. Acad. Sci USA 97:13269-74
171. Pan PY, Zang Y, Weber K, Meseck ML, Chen SH. 2002. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6:528-36
172. Vinay DS, Kwon BS. 1998. Role of 4-1BB in immune responses. Semin. Immunol. 10:481-89
173. Kwon BS, Weismann SM. 1989. cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. USA 86:1963-67
174. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. 2000. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur. J. Immunol. 30:392-102
175. Takahashi C, Mittler RS, Vella AT. 1999. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162:5037-40
176. Dawicki W, Watts TH. 2004. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur. J. Immunol. 34:743-51
177. Wen T, Bukczynski J, Watts TH. 2002. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production and the development of cytolytic effector function. J. Immunol. 168:4897-906
178. Tan JT, Ha J, Cho HR, Tucker-Burden C, Hendrix RC, et al. 2000. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation 70:175-83
179. Seo SK, Park HY, Choi JH, Kim WY, Kim YH, et al. 2003. Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J. Immunol. 171:576-83
180. Lyons PA, Hancock WW, Denny P, Lord CJ, Hill NJ, et al. 2000. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity 13:107-15
181. Watts TH, DeBenedette MA. 1999. T cell costimulatory molecules other than CD28. Curr. Opin. Immunol. 11:286-93
182. Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, et al. 2002. Cutting edge: expression of functional CD137 receptor by dendritic cells. J. Immunol. 168:4262-67
183. Kienzle G, von Kempis J. 2000. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int. Immunol. 12:73-82
184. Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H. 2002. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J. Leukoc. Biol. 72:35-42
185. + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 169:4230-36
186. Heinisch IV, Bizer C, Volgger W, Simon HU. 2001. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J. Allergy Clin. Immunol. 108:21-28
187. Reali C, Curto M, Sogos V, Scintu F, Pauly S, et al. 2003. Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2. J. Neurosci. Res. 74:67-73
188. Goodwin RG, Din WS, Davis-Smith T, Anderson DM, Gimpel SD, et al. 1993. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23:2631-41
189. Summers KL, Hock BD, McKenzie JL, Hart DN. 2001. Phenotypic characterization of five dendritic cell subsets in human tonsils. Am. J. Pathol. 159:285-95
190. Laderach D, Wesa A, Galy A. 2003. 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol 226:37-44
191. Seko Y, Takahashi N, Oshima H, Shimozato O, Akiba H, et al. 2001. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3. J. Pathol. 195:593-603
192. Seko Y, Sugishita K, Sato O, Takagi A, Tada Y, et al. 2004. Expression of costimulatory molecules (4-1BBL and Fas) and major histocompatibility class I chain-related A (MICA) in aortic tissue with Takayasu's arteritis. J. Vasc. Res. 41:84-90
193. Langstein J, Michel J, Fritsche J, Kreutz M, Andreesen R, Schwarz H. 1998. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J. Immunol. 160:2488-94
194. Langstein J, Schwarz H. 1999. Identification of CD137 as a potent monocyte survival factor. J. Leukoc. Biol. 65:829-33
195. Pollok KE, Kim Y-J, Hurtado J, Zhou Z, Kim KK, Kwon BS. 1994. 4-1BB T cell antigen binds to mature B cells and macrophages, and costimulates anti-μ-primed splenic B cells. Eur. J. Immunol. 24:367-74
196. - T cells. J. Immunol. 158:3081-89
197. + T cell responses. Nat. Immunol. 3:536-41
198. Bertram EM, Lau P, Watts TH. 2002. Temporal segregation of CD28 versus 4-1BBL-mediated costimulation: 4-1BBL influences T cell numbers late in the primary response and regulates the size of the memory response following influenza infection. J. Immunol. 168:3777-85
199. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, et al. 2002. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20:143-48
200. Cooper D, Bansal-Pakala P, Croft M. 2002. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur. J. Immunol. 32:521-29
201. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47-55
202. Hurtado JC, Kim YJ, Kwon BS. 1997. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158:2600-9
203. - T cells by 4-1BB ligand. Eur. J. Immunol. 33:446-54
204. + T cells. Cancer Res. 62:3459-65
205. Alderson MR, Smith CA, Tough TW, Davis-Smith T, Armitage RJ, et al. 1994. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24:2219-27
206. Kim YJ, Kim SH, Mantel P, Kwon BS. 1998. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur. J. Immunol. 28:881-90
207. Bukczynski J, Wen T, Ellefsen K, Gauldie J, Watts TH. 2004. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 101:1291-96
208. + T cells. Int. Immunol. 14:1155-67
209. + T cells. Blood 100:3253-60
210. Bansal-Pakala P, Croft M. 2002. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J. Immunol. 169:5005-9
211. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, et al. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:682-85
212. Bertram EM, Dawicki W, Sedgmen B, Bramson JL, Lynch DH, Watts TH. 2004. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J. Immunol. 172:981-88
213. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. 2001. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol. 166:3174-83
214. + cytolytic T lymphocytes in vivo. Blood 103:177-84
215. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. 1998. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190:167-72
216. Pan PY, Gu P, Li Q, Xu D, Weber K, Chen SH. 2004. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J. Immunol. 172:4779-89
217. - dependent manner. J. Immunol. 169:1792-800
218. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. 1999. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J. Exp. Med. 190:1535-40
219. Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. 2002. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. 8:1405-13
220. Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, et al. 2002. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168:1457-65
221. Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, et al. 2003. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J. Clin. Invest. 111:1505-18
222. Wu ZQ, Khan AQ, Shen Y, Wolcott KM, Dawicki W, et al. 2003. 4-1BB (CD137) differentially regulates murine in vivo protein- and polysaccharide-specific immunoglobulin isotype responses to Streptococcus pneumoniae. Infect. Immun. 71:196-204
223. Zhu G, Flies DB, Tamada K, Sun Y, Rodriguez M. 2001. Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/1-Eα- transgenic mice. J. Immunol. 167:2671-76
224. Myers L, Takahashi C, Mittler RS, Rossi RJ, Vella AT. 2003. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc. Natl. Acad. Sci. USA 100:5348-53
225. DeBenedette MA, Wen T, Bachmann MF, Ohashi PS, Barber BH, et al. 1999. Analysis of 4-1BB ligand-deficient mice and of mice lacking both 4-1BB ligand and CD28 reveals a role for 4-1BB ligand in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 163:4833-41
226. Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP. 1999. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J. Immunol. 163:4859-68
227. Kwon BS, Hurtado JC, Lee ZH, Kwack KB, Seo SK, et al. 2002. Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168:5483-90
228. Shedlock DJ, Whitmire JK, Tan J, MacDonald AS, Ahmed R, Shen H. 2003. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J. Immunol. 170:2053-63
229. Tan JT, Whitmire JK, Murali-Krishna K, Ahmed R, Altman JD, et al. 2000. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J. Immunol. 164:2320-25
230. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28:1116-21
231. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 1999. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol. 162:5003-10
232. Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, et al. 2000. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J. Natl. Cancer Inst. 92:931-36
233. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. 2003. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-κB (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. J. Immunol. 171:4121-30
234. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. 2002. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat. Med. 8:343-48
235. Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 2001. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell Immunol. 210:56-65
236. Vonderheide RH, June CH. 2003. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol. Res. 27:341-56
237. Montgomery RI, Warner MS, Lum BJ, Spear PG. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-36
238. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, et al. 1998. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8:21-30
239. Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, et al. 1998. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. Clin. Invest. 102:1142-51
240. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. 1999. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274:13733-36
241. Granger SW, Rickert S. 2003. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev. 14:289-96
242. Granger SW, Ware CF. 2001. Turning on LIGHT. J. Clin. Invest. 108:1741-42
243. Morel Y, Schiano de Colella JM, Harrop J, Deen KC, Holmes SD, et al. 2000. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J. Immunol. 165:4397-404
244. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, et al. 2000. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 164:4105-10
245. Morel Y, Truneh A, Sweet RW, Olive D, Costello RT. 2001. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 167:2479-86
246. Ye Q, Fraser CC, Gao W, Wang L, Busfield SJ, et al. 2002. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J. Exp. Med. 195:795-800
247. Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, et al. 2000. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6:283-89
248. Yu P, Lee Y, Liu W, Chin RK, Wang J, et al. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5:141-49
249. La S, Kim J, Kwon BS, Kwon B. 2002. Herpes simplex virus type 1 glycoprotein D inhibits T-cell proliferation. Mol. Cells 14:398-403
250. Wang J, Lo JC, Foster A, Yu P, Chen HM, et al. 2001. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108:1771-80
251. Harrop JA, Reddy M, Dede K, Brigham-Burke M, Lyn S, et al. 1998. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J. Immunol. 161:1786-94
252. + T cell expansion, but not effector function. Int. Immunol. 15:861-70
253. Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K. 2002. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin β in mesenteric lymph node genesis. J. Exp. Med. 195:1613-24
254. + T cell function in mice lacking the TNF superfamily member LIGHT. J. Immunol. 168:4832-35
255. Morel Y, Truneh A, Costello RT, Olive D. 2003. LIGHT, a new TNF superfamily member, is essential for memory T helper cell-mediated activation of dendritic cells. Eur. J. Immunol. 33:3213-19
256. Shi G, Wu Y, Zhang J, Wu J. 2003. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J. Immunol. 171:3407-14
257. Shi G, Luo H, Wan X, Salcedo TW, Zhang J, Wu J. 2002. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood 100:3279-86
258. Wan X, Zhang J, Luo H, Shi G, Kapnik E, et al. 2002. A TNF family member LIGHT transduces costimulatory signals into human T cells. J. Immunol. 169:6813-21
259. Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, et al. 2001. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J. Immunol. 167:6330-37
260. Wang J, Lo JC, Foster A, Yu P, Chen HM, et al. 2001. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest, 108:1771-80
261. Wang J, Anders RA, Wu Q, Peng D, Cho JH, et al. 2004. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J. Clin. Invest. 113:826-35
262. Wang J, Fu YX. 2003. LIGHT (a cellular ligand for herpes virus entry mediator and lymphotoxin receptor)-mediated thymocyte deletion is dependent on the interaction between TCR and MHC/self-peptide. J. Immunol. 170:3986-93
263. Kwon BS, Tan KB, Ni J, Oh KO, Lee ZH, et al. 1997. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272:14272-76
264. Tamada K, Tamura H, Flies D, Fu YX, Celis E, et al. 2002. Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J. Clin. Invest. 109:549-57
265. Rooney IA, Butrovich KD, Glass AA, Borboroglu S, Benedict CA, et al. 2000. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275:14307-15
266. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, et al. 1982. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299:65-67
267. Horie R, Higashihara M, Watanabe T. 2003. Hodgkin's lymphoma and CD30 signal transduction. Int. J. Hematol. 77:37-47
268. Horie R, Watanabe T. 1998. CD30: expression and function in health and disease. Semin. Immunol. 10:457-70
269. Biswas P, Rovere P, De Filippi C, Heltai S, Smith C, et al. 2000. Engagement of CD30 shapes the secretion of cytokines by human γδ T cells. Eur. J. Immunol. 30:2172-80
270. Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. 2004. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J. Immunol. 172:2186-93
271. Romagnani P, Annunziato F, Manetti R, Mavilia C, Lasagni L, et al. 1998. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 91:3323-32
272. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. 1995. CD30 and type 2 T helper (Th2) responses. J. Leukoc. Biol. 57:726-30
273. Tarkowski M. 2003. Expression and a role of CD30 in regulation of T-cell activity. Curr. Opin. Hematol. 10:267-71
274. Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB. 1998. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J. Immunol. 160:2180-87
275. Toennies HM, Green JM, Arch RH. 2004. Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms. J. Leukoc. Biol. 75:350-57
276. Younes A, Consoli U, Zhao S, Snell V, Thomas E, et al. 1996. CD30 ligandis expressed on resting normal and malignant human B lymphocytes. Br. J. Haematol. 93:569-71
277. Wiley SR, Goodwin RG, Smith CA. 1996. Reverse signaling via CD30 ligand. J. Immunol. 157:3635-39
278. Shimozato O, Takeda K, Yagita H, Okumura K. 1999. Expression of CD30 ligand (CD153) on murine activated T cells. Biochem. Biophys. Res. Commun. 256:519-26
279. Seko Y, Ishiyama S, Nishikawa T, Kasajima T, Hiroe M, et al. 2002. Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy. Cardiovasc. Pathol. 11:166-70
280. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-60
281. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. 1996. Structure and expression of murine CD30 and its role in cytokine production. J. Immunol. 156:442-49
282. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. 1994. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045-56
283. Muta H, Boise LH, Fang L, Podack ER. 2000. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J. Immunol. 165:5105-11
284. Duckett CS, Thompson CB. 1997. CD-30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 11:2810-21
285. Del Prete G, De Carli M, D'Elios MM, Daniel KC, Almerigogna F, et al. 1995. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J. Exp. Med. 182:1655-61
286. Wynn TA. 2003. IL-13 effector functions. Annu. Rev. Immunol. 21:425-56
287. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, et al. 1996. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84:551-62
288. DeYoung AL, Duramad O, Winoto A. 2000. The TNF receptor family member CD30 is not essential for negative selection. J. Immunol. 165:6170-73
289. Podack ER, Strbo N, Sotosec V, Muta H. 2002. CD30-governor of memory T cells? Ann. NY Acad. Sci. 975:101-13
290. Siegmund T, Armitage N, Wicker LS, Peterson LB, Todd JA, Lyons PA. 2000. Analysis of the mouse CD30 gene: a candidate for the NOD mouse type 1 diabetes locus Idd9.2. Diabetes 49:1612-16
291. Chakrabarty S, Nagata M, Yasuda H, Wen L, Nakayama M, et al. 2003. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin. Exp. Immunol. 133:318-25
292. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. 1999. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398:341-44
293. Nocentini G, Giunchi L, Ronchetti S, Krausz LT, Bartoli A, et al. 1997. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc. Natl. Acad. Sci. USA 94:6216-21
294. + T cells. J. Immunol. 173:5008-20
295. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311-23
296. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:135-42
297. Kim JD, Choi BK, Bae JS, Lee UH, Han IS, et al. 2003. Cloning and characterization of GITR ligand. Genes Immun. 4:564-69
298. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, et al. 2003. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl. Acad. Sci. USA 100:15059-64
299. Yu KY, Kim HS, Song SY, Min SS, Jeong JJ, Youn BS. 2003. Identification of a ligand for glucocorticoid-induced tumor necrosis factor receptor constitutively expressed in dendritic cells. Biochem. Biophys. Res. Commun. 310:433-38
300. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, et al. 2004. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur. J. Immunol. 34:613-22
301. + T cell activation and experimental autoimmune encephalomyelitis. J. Immunol. 172:4686-90
302. Ronchetti S, Nocentini G, Riccardi C, Pandolfi PP. 2002. Role of GITR in activation response of T lymphocytes. Blood 100:350-52
303. + T cells. Curr. Opin. Immunol. 15:690-96
304. + regulatory T cells. J. Immunol. 171:708-16
305. + T cells. J. Leukoc. Biol. 75:785-91
306. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, et al. 2004. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172:3580-89
307. Bertram EM, Dawicki W, Watts TH. 2004. Role of T cell costimulation in anti-viral immunity. Semin. Immunol. 16:185-96
308. Ye H, Park YC, Kreishman M, Kieff E, Wu H. 1999. The structural basis for the recognition of diverse receptor se quences by TRAF2. Mol. Cell 4:321-30
309. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. 1995. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243-52
310. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, et al. 2003. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat. Immunol. 4:49-54
311. Wang J, Chun T, Lo JC, Wu Q, Wang Y, et al. 2001. The critical role of LIGHT, a TNF family member, in T cell development. J. Immunol. 167:5099-105